Abstract-The paraoxonase (PON1) PON1-Q192R and PON1-L55M polymorphisms have been inconsistently associated with vascular disease. Plasma PON1 activity phenotypes vary markedly within genotypes and were, therefore, expected to add to the informativeness of genotype for predicting vascular disease. The case-control sample included 212 ageand race-matched men (mean age 66.4 years). The 106 carotid artery disease (CAAD) cases had Ͼ80% carotid stenosis, and the 106 controls had Ͻ15%. [15] [16] [17] The cardioprotective role of HDL, the inhibition or reduction of atherogenic LDL oxidation, appears to be, in large part, a function of PON1, which is associated with HDL. 18 -22 PON1 metabolizes mildly oxidized phospholipids, presumably by eliminating hydroperoxy derivatives of unsaturated fatty acids. 20 Thus, the PON1-CVD association is expected to result from the role of PON1 in the metabolism of bioactive lipid molecules and protection against damage due to oxidized LDL.
T he paraoxonase (PON1) gene maps to human chromosome 7q21-22 and has 2 common coding region polymorphisms, PON1 Q192R , the Gln (Q) to Arg (R) substitution at amino acid 192, and PON1 L55M , the Leu (L) to Met (M) substitution at amino acid 55. The PON1 192R allele or PON1 192RR genotype have been found to be associated with cardiovascular disease (CVD) in many, [1] [2] [3] [4] [5] [6] [7] but not all, 8 -13 studies. The PON1 55LL genotype predicted CVD in several studies, 14, 15 including an Australian sample in which PON1 192 genotype did not predict disease, 12 but not in an Asian Indian sample in which PON1 192 genotype did predict CVD. 4, 15 The PON1 R192 and PON1 L55 alleles are in strong linkage disequilibrium in several ethnic groups. [15] [16] [17] The cardioprotective role of HDL, the inhibition or reduction of atherogenic LDL oxidation, appears to be, in large part, a function of PON1, which is associated with HDL. 18 -22 PON1 metabolizes mildly oxidized phospholipids, presumably by eliminating hydroperoxy derivatives of unsaturated fatty acids. 20 Thus, the PON1-CVD association is expected to result from the role of PON1 in the metabolism of bioactive lipid molecules and protection against damage due to oxidized LDL.
PON1 hydrolyzes a variety of substrates, including the toxic components of the pesticides parathion, chlorpyrifos, and diazinon; aryl esters, such as phenyl acetate; and the nerve agents soman and sarin. There is 10-to 40-fold interindividual variability in rates of paraoxon hydrolysis. 23 The PON1 192Q allele has the higher rate of in vitro hydrolysis of diazoxon, sarin, and soman, 24 whereas the PON1 192R allele has higher activity for the hydrolysis of paraoxon and chlorpyrifos oxon. 24, 25 These rates of substrate hydrolysis are quite variable within PON1 genotypes (at least 13-fold) and represent phenotypes that can add information about PON1 status beyond genotyping alone. 24 Paraoxon hydrolysis activity is lost in the plasma of the PON1 knockout mouse, and these mice are more susceptible to atherosclerosis. 26 We compared the PON1 192 and PON1 55 genotypes with PON1 rates of hydrolysis of paraoxon (POase activity) and diazoxon (DZOase activity) for their predictiveness in vascular disease of the carotid arteries. These 2 substrates were chosen because, relative to the other isoform, the PON1 192Q isoform has a higher DZOase activity and the PON1 192R isoform has a higher POase activity in the in vitro assays. The resulting 2D plot ( Figure 1 ) allows an accurate inference of PON1 192 genotype, in addition to providing PON1 phenotype information. 27 
Methods

Sample
All subjects were collected through an Epidemiology Research and Information Center project at the Puget Sounds Veterans Affairs Health Care System (PSVAHCS). All cases had severe carotid artery disease (CAAD), ie, Ͼ80% internal carotid artery stenosis, unilaterally or bilaterally, on angiography with the use of standardized guidelines, or they had carotid endarterectomy without prior angiogram. All controls were drawn from patients without codes for vascular disease and subsequently were shown to have had Ͻ15% internal carotid artery stenosis, bilaterally, on carotid ultrasound with the use of standardized guidelines. Any subjects with total serum cholesterol Ͼ400 mg/dL or coagulopathy were excluded. Subjects were matched by race and censored age (within 12 months). Race was ascertained from PSVAHCS record and self-report. Censored age matching was based on the age at the time of the blood draw for controls and the age at the diagnosis of vascular disease for cases. The mean duration of documented vascular disease before the sampling of cases was 2.6 years. The present study was approved by the University of Washington and the PSVAHCS human subject review processes. Subjects gave written informed consent.
The subjects were US military veterans (mean censored age 66.4 years, range 49 to 82 years). Of the 212 subjects, all were male, 95% were white, 26% were on lipid-lowering medications, and 66% were current or former smokers (Table 1 ). Smoking history was by self-report. The presence of treatment with antihypertensive drugs or lipid-lowering medications was abstracted by a physician from the patient's pharmacy medication history. Type 2 diabetes was considered present if the subject took oral hypoglycemics or insulin or if he had a hemoglobin A 1C Ͼ7.0.
PON1 Genotype and Activity Phenotype Methods
DNA was prepared from buffy coat preparations by a modification of the procedure of Miller et al 28 with the use of Puregene reagents (Gentra). PON1 192 and PON1 55 genotypes were determined by polymerase chain reaction techniques and AlwI and NlaIII restriction enzyme analysis. 25 Genotype distributions did not significantly differ from Hardy-Weinberg equilibrium expectations.
POase activity and DZOase activity were measured spectrophotometrically with lithium heparin plasma, as described. 27 All samples were run in duplicate; the averaged value was used for analysis. PON1 192 genotype can be predicted with high accuracy from examination of the 2D plot of paraoxon and diazoxon hydrolysis rates. 27 When assignments did not match, both genotyping and phenotyping studies were repeated. All 212 subjects had genotype-phenotype agreement (Figure 1 ), resulting in an expected nearly 100% genotype accuracy.
Lipid Measurements
Lipid measurements were performed on fasting whole plasma. Standard enzymatic methods were used to determine levels of total cholesterol, triglycerides, and HDL cholesterol on an Abbott Spectrum analyzer. 29 -31 LDL cholesterol was calculated. 32 HDL subfractions 2 and 3 were determined by precipitation of HDL2 from total HDL and measurement of the HDL3 remaining in the supernatant. ApoA-I measurement methods were as previously reported. 33 
Statistical Methods
Logistic regression was used to test for POase and DZOase activity effect in the prediction of CAAD cases (coded as 1) versus controls (coded as 0). Current age was included as a covariate. A Wald statistic was used to test for significance of the effect at the 0.05 level. Separate logistic regressions were tested for a PON1 192 and PON1 55 genotype or combined haplotype effect on the prediction of CAAD status. Another logistic regression tested whether the addition of genotype or combined haplotype information altered the significance of POase and/or DZOase in the prediction of CAAD status. POase, DZOase, and lipid-related measures were transformed by natural logarithm (ln) because of positive skew. Combined haplotype was considered as an alternative to genotype, to allow for joint PON1 192 and PON1 155 effects or to allow for the possibility that any genotypic effects observed may be due to linkage disequilibrium of the genotype with another etiologic polymorphism. Combined haplotypes (both haplotypes, per subject) were constructed for the PON1 polymorphisms ( Table 2 ), assuming that all PON1 192QR -PON1 55LM subjects had haplotypes MQ and LR; this assumption was based on the rarity of the MR haplotype. The combined haplotypes MQ/MR and LR/MR each had only 1 occurrence and were dropped from On lipid-lowering medication, % 38 18
On antihypertensives, % 62 61
Ever smoked, % 77 57
Smoking, mean pack-years 37. haplotype analyses, except for the computation of genetic variance. Genotype or combined haplotype were evaluated as grouped dummy variables, with PON1 192QQ , PON1 55LL , and combined haplotype LQ/LQ as the reference groups. Backward stepwise logistic regression (with use of the likelihood ratio criterion) was used to determine whether the predictive power of POase and DZOase was independent of other factors, with age held as a covariate in the model. There was no statistically significant (at PՅ0.05) relationship of POase or DZOase with age in the cases or controls. All analyses used SPSS 8.0 for Windows, 34 except for computation of the portion of the total variance (VT) due to genetic variance (V G ), which was computed as V G /VT.
Results Preliminary Analyses: Relationship of PON1
Genotypes and Phenotypes
As expected, POase and DZOase are highly correlated within the PON1 192 genotype or combined haplotypes (Table 2, Figure 1 ). The POase and DZOase activity levels are not correlated within the PON1 55LL or PON1 55LM genotype. They were correlated within the PON1 55MM genotype; however, this is likely secondary to the preponderance of PON1 192QQ genotypes in that group, which is due to linkage disequilibrium between PON1 192Q and PON1 55M . PON1 192 and PON1 55 genotypes or combined haplotypes predicted significant variation in ln POase and ln DZOase for both cases and controls (ANOVA, all PϽ0.01), except that the PON1 55 genotype did not predict significant variation within ln DZOase in the controls. The portion of the total variance in POase and DZOase attributable to genotype or combined haplotype effects is shown in Table 2 . The 2 singly occurring combined haplotypes were included in these calculations.
Activity Phenotypes Predicted Vascular Disease
The ln DZOase activity phenotype significantly predicted severe CAAD (CAAD case, coded as 1) versus control (coded as 0) status (Pϭ0.005), by use of logistic regression with age at blood draw (current age) as a covariate. The exponential logistic regression coefficient (Exp-␤) was 0.32, with a 95% CI of 0.14 to 0.70. The ln POase activity phenotype also significantly predicted CAAD case versus control status (Pϭ0.019), by use of logistic regression with age (current age) as a covariate. For ln POase, Exp-␤ was 0.63 (95% CI 0.43 to 0.93). By use of a likelihood ratio test (LRT) to compare nested models, ln DZOase (Pϭ0.006) and ln POase (Pϭ0.023) added to the prediction of CAAD status. In the model including age, ln DZOase, and ln POase as predictors, the exponential coefficients were 0.31 (95% CI 0.14 to 0.71) for ln DZOase and 0.63 (95% CI 0.42 to 0.94) for ln POase.
CAAD cases had significantly lower levels of POase activity (25% reduced) and DZOase activity (16% reduced), see Table 2 . The plot of POase versus DZOase activity demonstrated that the cases had lower joint activities without loss of the PON1 192 genotype-specific ratios of rates of substrate hydrolysis (Figure 1 ). This was particularly notable for the PON1 192QQ genotype. (data not shown). The same pattern of decreased PON1 hydrolysis rates was seen within each PON1 192 genotype, except for the PON1 192RR genotype ( Figure 2 , Table 2 ). The trend of lower activity phenotypes in the cases was also seen within each PON1 55 genotype (Table 2 ). This trend is also noted in the combined haplotypes, except for the MQ/LR and LR/LR combined haplotypes.
Activity Phenotype Effects Were Independent of Other Risk Factors in CAAD Prediction
When ln total cholesterol, ln LDL cholesterol, ln triglycerides, ln apoA-I, ln HDL cholesterol, ln HDL2, ln HDL3, and ln pack-years of smoking were considered in the logistic regression model in addition to ln POase and ln DZOase (and age), ln DZOase remained a statistically significant predictor (Pϭ0. 
Discussion
The previously examined determinants of POase activity include PON1 192 genotype, 25 PON1 55 genotype, 35 and the serum concentration of PON1. 35 Variation within genotypes, it has been suggested, is primarily due to the variability in PON1 concentration, 36, 37 hence the correlation of POase and DZOase activities within, but not among, PON1 192 genotypes (Figure 1 ). One study reported that POase activity was determined 46% by PON1 192 genotype, 16% by PON1 55 genotype, and 13% by PON1 concentration. 35 Cigarette smoke extract has been shown to inhibit POase activity in vitro, 38 and lipid, lipoprotein, or apolipoprotein levels have been weakly associated with PON1 activity or genotype in some, 11, 17, 39, 40 but not all, 3, 35 studies. PON1 55 genotype was predictive of PON1 concentration in a study of diabetics, 37 but this was not found in a study of nondiabetics. 35 The lowered POase and DZOase activity seen in cases in the present study may be best attributed to lowered PON1 serum concentration.
Given the large variation in PON1 activities within PON1 192 and PON1 55 genotypes seen in the present study and elsewhere, 24, 27, 41 it is not surprising that the PON1 activity phenotypes provided additional information about risk of vascular disease that was not provided by genotype alone. However, no genotype effect was detectable unless activity phenotype was also considered, even though the PON1 192 and/or PON1 55 genotypes account for a large portion of the variation in POase and DZOase activity. Interestingly, we found that DZOase activity, which is substantially less affected by the PON1 192 and PON1 55 polymorphisms, was more predictive of disease status than was POase activity in a marginal analysis. Smoking did depress DZOase activity, but increased smoking in cases accounted for only 1% of the case-control DZOase activity difference (data not shown). We have shown that the predictive power of PON1 activity for CAAD is not due to any correlations with smoking and lipid levels. The dramatically lowered phenotype activities observed in a subset of the vascular disease subjects may represent phenomena such as promoter mutations. However, most of the cases are shifted toward lower activities, relative to the control subjects. This suggests that the factor(s) responsible for lowering the activities is not rare.
Our results are consistent with a recent study that found that reduced POase activity, but not marginal PON1 192 or PON1 55 genotype, predicted retinopathy and proteinuria in non-insulin-dependent diabetics. 42 Our results also suggest that the lowered POase activity reported in myocardial infarction survivors, also without a genotype effect, 43 was a risk factor rather than the result of the infarction. The current cohort was older and had a high proportion of smokers. Although this is representative of vascular disease patients, this demographic may differ from some studies that have detected PON1 genotype effects on vascular disease without consideration of PON1 phenotypes. [1] [2] [3] [4] [5] [6] [7] 12, 14, 15 The POase and DZOase enzyme activity phenotypes clearly add information about CAAD risk in this cohort and should help clarify the relation of genetic polymorphisms to disease risk. This result should encourage investigators to reevaluate the currently common polymerase chain reactiononly technology when exploring the role of PON1 in vascular disease and other diseases. It raises the broader question of whether it is efficient to study genetic associations without also examining expression. One or more important modifiers of PON1 exist, play a role in atherogenesis, and are not reflected by the PON1 192 and PON1 55 polymorphisms. This may contribute to the conflicting results found when evaluating the association of these polymorphisms with vascular disease risk.
